povetacicept
Phase 2- Indications
- IgA nephropathy, Membranous nephropathy, Lupus nephritis, Autoimmune cytopenias
Company intelligence / Profile preview
Alpine Immune Sciences, Inc.
Seattle, Washington, United Statesinvestors.vrtx.com ↗
- Ownership
- Public · ALPN
- Employees
- ~142
- Development stage
- Phase 3
01
Overview
Alpine Immune Sciences has demonstrated strong clinical results with its lead candidate povetacicept in IgA nephropathy. In a Phase I/IIa trial, povetacicept achieved over a 60% reduction in urine protein to creatinine ratio at week 36 and remission in most patients. The company has completed a successful end-of-phase II meeting with the FDA and plans to initiate a pivotal Phase III trial. Additional programs target other autoimmune diseases including SLE and cytopenias[5][7][8].
- Therapeutic areas
- HematologyImmunologyNephrology
- Modalities
- Protein-based immunotherapiesBispecific antibodiesFusion proteinsSmall molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Strategic collaborations with leading global biopharmaceutical companies; specific partners not named but includes Adaptimmune for SPEAR T-cell therapies[4][9].
04
Financials
- Market cap
- $4.5B
- Total revenue
- $7M
- Enterprise value
- $4.2B
Beyond the preview
Go deeper on Alpine Immune Sciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpine Immune Sciences, Inc..